SHEET 1	OF #	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4806-7	SERIAL NO. 10/775574
PE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT Barone, Jr. et al.	
S NOW WE	FILING DATE February 9, 2004	GROUP ART 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
PL	A1.	5,985,860	11/16/99	Торро	514	159	
A	A2.	5,496,827	3/5/96	Patrick	514	310	
	A3.	5,451,407	9/19/95	Cormier et al.	424	448	
	A4.	5,318,960	6/7/94	Toppos	-514	159	
	A5.	5,240,945	8/31/93	Warshaw	514	356	-
	A6.	5,232,935	8/3/93	Colaset	514	356	
	A7.	2004/0102358	5/27/04	Scivoletto	514	1	
	A8.	2003/0059484 A1	3/3/2003	Bonte et al.	424	9.2	
	A9.	2002/0183297	12/502	Niazi	514	178	
PU	A10.	2002/0165429 A1	7/11/2002	Thompson	600	38	

FOREIGN PATENT DOCUMENTS

		·			SUB CLASS	TRANSL	ATION
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS		YES	NO
A11		·	·				·
A12						_	

		}				•
EXAM	NER JACK	Trecea Lu	Th	DATE CONSIDERED	8/17/05	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known								
Application Number	10/775574							
Filing Date	February 9, 2004							
First Named Inventor	Barone, Jr.							
Art Unit	1614							
Examiner Name								
Attorney Docket Number	5370-7							

U.S. PATENT DOCUMENTS										
Examiner Initials*	Cite No.1	Document Number Number-kind Code ^{2 (# known)}	Publication Date	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear					
ρU	1.	US-5,217,997	June 8, 1993	5,217,997	·					
	2.	US-5,232,935	August 3, 1993	5,232,935						
	3.	US-5,240,945	August 31, 1993	5,240,945	,					
	4.	US-5,318,960	June 7, 1994	5,318,960						
	5.	US-5,428,070	June 27, 1995	5,428,070						
	6.	US-5,451,407	September 19, 1995	5,451,407						
	7.	US-5,496,827	March 5, 1996	5,496,827						
	8.	US-5,543,430	August 6, 1996	5,543,430						
	9.	US-5,595,753	January 21, 1997	5,595,753						
	10.	US-5,767,160	June 16, 1998	5,767,160						
	11.	US-5,891,459	April 6, 1999	5,891,459						
	12.	US-5,895,658	April 20, 1999	5,895,658						
	13.	US-5,922,332	July 13, 1999	5,922,332						
	14.	US-5,985,860	November 16, 1999	5,985,860	·					
	15.	US-6,007,824	December 28, 1999	6,007,824						
	16.	US-6,117,872	September 12, 2000	6,117,872						
	17.	US-6,207,713	March 27, 2001	6,207,713						
	18.	US-6,294,517	September 25, 2001	6,294,517						
	19.	US-6,323,211	November 27, 2001	6,323,211						
	20.	US-6,368,640	April 9, 2002	6,368,640						
	21.	US-6,428,791	August 6, 2002	6,428,791						
	22.	US-6,476,037	November 5, 2002	6,476,037						
B	23.	US-6,544,563	April 8, 2003	6,544,563						
PU	24.	US-6,548,087	April 15, 2003	6,548,087						

	aminer jature	tel	week	Lever	·	Date Considered	8/17/	05	
*EY	ARAINED	Initial if safaras	an in Annaidean	umathar ar not aitati	an in in conformance and a	-1	Associated a		

communication to applicant.

Complete if Known Substitute for form 1449A/PTO **Application Number** 10/775574 Filing Date February 9, 2004 **INFORMATION DISCLOSURE** First Named Inventor Barone, Jr. STATEMENT BY APPLICANT Art Unit 1614 **Examiner Name** Sheet **Attorney Docket Number** 5370-7

PC	25.	US-6,548,841	October 1, 2002	6,458,841	
M	26.	US-6,579,543	June 17, 2003	6,579,543	
	27. US-6,646,006		November 11, 2003	6,646,006	
	28.	US-2002-0151592	October 17, 2002	20020151592A2	
	29.	US-2002-0183297	December 5, 2002	20020183297A1	
	30.	US-2003-0077296	April 24, 2003	20030077296A1	
PU	31.	US-2004-0102358	May 27, 2004	20040102358A1	

,				FOREI	GN PATENT DO	DCUMENTS		
Examiner Initials*	Cite No.1	Country C	Foreign Patent Document Country Code ³ ; Number ⁴ ; Kind Code ³ (if known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Le
		PCT	T-					\top
			1-		1			T
			-					
•			Ţ-					\top
			<u> -</u>					Т
			<u> </u>					T
			-					1

		OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)
Examiner Cite Initials* No.1		
PL	32.	Burnett A.L., Chang, A.G., Crone, J.K., Huang, P.L., Sezen, S.F., Noncholinergic Penile Erection in Mice lacking the gene for endothelial nitric oxide synthase. J. Andrology 23(1):92-97 (2002).
d !	33.	Cellek S, Moncada S, Ņitrergic neurotransmission mediates the non-adrenergic non-cholinergic responses in the clitoral corpus cavernosum of the rabbit. Br. J. Pharmacol. 125(8):1627-9 (1998).
	34.	Christianson DW, Arginase: structure, mechanism, and physiological role in male and female sexual arousal. Acc. Chem. Res. 38(3):191-201 (2005).
PL	35.	Elsner, P., Maibach, H.I. Cutaneous response to topical methyl nicotinate in human forearm and vulvar skin. J. Dermatol. Sci. 2(5):341-5 (1991).
Alle	36.	Finnin, B., Transdermal Substance Delivery-What to Expect in the Near Future. Business Briefing: Pharmatech., pp. 182-193. (2003). Office copy is likes ible new Re

*EXAMINER: Initial if reference is considered whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Sigature Date Considered

S.	bstitute for form	1.4.40A/DTO		Complete if Known		
30	osalgle for form	144370110		Application Number	10/775574	
l in	IFORMAT	TION DISC	CLOSURE	Filing Date	February 9, 2004	
		NT BY AP		First Named Inventor	Barone, Jr.	
	.,			Art Unit	1614	
				Examiner Name		
Sheet	Sheet 3 of 4		Attomey Docket Number	5370-7		

pc/	37.	Gonzalez-Cadavid NF, Rajfer J, Therapy of erectile dysfunction. Endocrine 23(2-3):167-76 (2004).	
91	38.	Gragasin FS, Michelakis ED, Hogan A, Moudgil R, Hashimoto K, Wu X, Bonnet S, Haromy A, Archer SL, The neurovascular mechanism of clitoral erection: nitric oxide and cGMP-stimulated activation of BKCa channels. FASEB J. 18(12):1382-91 (2004).	
7	39.	Guy, RH, Maibach, HI., Rapid radial transport of methyl nicotinate in the dermis, Archives Dermatol. Res. 273:91-95 (1982).	
/	40.	Irritants, Rubefacients and Vesicants, in Remington's Pharmaceutical Sciences 17th Edition, Mack Publishing Company, Eaton, Pennsylvania, p. 782, (1985).	
. /	41.	Ito TY, Trant AS, Polan ML., A double-blind placebo-controlled study of ArginMax, a nutritional supplement for enhancement of female sexual function. J. Sex Mantal Ther. 27(5):541-9 (2001).	
1	42.	Kim NN, Christianson DW, Traish AM, Role of arginase in the male and female sexual arousal respon J. Nutr. 134(10 Suppl):2873S-2879S; discussion 2895S (2004).	
	43.	Klotz, T. Mathers, M.J. Braun, M., Bloch, W., Englemann, U. Effectiveness of oral L-arginine in first-line treatment of erectile dysfunction in a controlled crossover study. Urol. Int. 63(4):220-23 (1999).	
	44.	Lebret, T, Herve JM, Gorny P, Worcel M, Botto H., Efficacy and safety of a novel combination of L-arginine glutamate and yohlmbine hydrochloride: a new oral therapy for erectile dysfunction. Eur. Urol. 41(6):608-13; discussion 613 (2002).	
(45.	McKay, D., Nutrients and botanicals for erectile dysfunction: examining the evidence. Altern. Med. Rev. 9(1):4-16 (2004).	
	46.	Meston CM, Worcel M, The effects of yohimbine plus L-arginine glutamate on sexual arousal in postmenopausal women with sexual arousal disorder. Arch. Sex Behav. 31(4):323-32 (2002).	
	47.	Moncada S., Higgs EA. Molecular mechanisms and therapeutic strategies related to nitric oxide. FAS 9:1319-1330 (1995).	
	48.	Muller, B., Kasper, M., Surber, C., Imanidis G., Permeation, metabolism and site of action concentrati of nicotinic acid derivatives in human skin Correlation with topical pharmacological effect. Eu. J. Phar Sci. 20:181-95 (2003).	
	49.	Park JK, Kim SZ, Kim SH, Kim YG, Cho KW, Renin angiotensin system of rabbit clitoral cavernosum: interaction with nitric oxide. J. Urol. 164(2):556-61 (2000).	
	50.	Park JK, Kim JU, Lee SO, Hwang PH, Yi HK, Kim YG, Cho KW, Nitric oxide-cyclic GMP signaling pathway in the regulation of rabbit clitoral cavernosum tone. Exp. Biol. Med. 227(11):1022-30 (2002).	
	51.	Sample of CONNECTION™ packaging including ingredient list, enclosed herewith.	
1	52.	Sivamani RK, Stoeber B, Wu GC, Zhai H, Liepmann D, Maibach H., Clinical microneedle injection of methyl nicotinate: stratum comeum penetration. Skin Res. Technol. 11(2):152-6 (2005).	
PC 53.		Stanislavov R, Nikolova V., Treatment of erectile dysfunction with pycnogenol and L-arginine. J. Sex Marital Ther. 29(3):207-13 (2003).	

Examiner Solitecta Leth Date Considered 8/17/05

EXAMINES: Initial if reference is considered that the example in the second sec

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	10/775574
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	February 9, 2004
				First Named Inventor	Barone, Jr.
				Art Unit	1614
	•			Examiner Name	
heet	4	of	4	Attorney Docket Number	5370-7

PL	54.	Web page from the Better Business Bureau of Metropolitan New York, Inc., April 21, 2005.
PL	55.	Woolfson AD, Malcolm RK, Campbell K, Jones DS, Russell JA., Rheological, mechanical and membrane penetration properties of novel dual drug systems for percutaneous delivery. J Control Release. 3;67(2-3):395-408 (2000).

Examiner Sigature Path Date Considered 8/17/05

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.